多西他赛和吡柔比星新辅助化疗乳腺癌临床疗效分析

Analysis of clinical efficacy of neoadjuvant chemotherapy containing pirarubicin and docetacel in treatment of breast cancer

目的研究应用多西他赛加吡柔比星行乳腺癌新辅助化疗的疗效评价及影响因素。方法检测87例乳腺癌新辅助化疗患者术前穿刺和术后病理学标本,做免疫组化检测ER、PR、CerbB-2,行新辅助化疗,分析获得病理学完全缓解(pCR)与患者年龄、病期、化疗周期数及ER、PR、CerbB-2表达的相关性。结果ER(+)的患者获得pCR(6.1%)比ER(-)的患者(29.0%)低(P<0.01);PR(+)的患者获得pCR(11.1%)比PR(-)的患者(29.2%)低(P<0.05);CerbB-2过表达患者pCR率(20.0%)高于非CerbB-2过表达者(15.0%),但是差异无显著性(P=0.8452),年龄、病期、化疗周期数与pCR无明显相关性。结论ER、PR阴性表达的患者对多西他赛加吡柔比星治疗反应性好。

Objective To study the efficacy of neoadjuvant chemotherapy （NAC） containing THP and docetaxel in treatment of breast cancer and its influential factors. Methods The expression of ER, PR and CerbB-2 in breast cancer tissue of patients receiving NAC were detected by immunohistochemical method. The correlation of ER, PR and CerbB-2 with pathological complete response （pCR） was analysed. Resuits ER and PR expressions was signifieantly correlated to treatment response,the pCR rates were 6. 1% and 11.1% in ER and PR positive tumors respeetively, while they were 28.9% and 29. 2% in the ER and PR negative tumors（P 〈 0. 05）. No correlation was observed between the pCR and CerbB-2 expression,age, stage and number of cycles of chemotherapy. Conclusion The ER and PR may be the important indexes for treatment and prognosis of breast cancer patients receiving neoadjuvant chemotherapy.